A Randomized, Multicenter, Open-Label, Phase 2 Study of VELCADE Alone or VELCADE Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Millennium Pharmaceuticals, Inc.20 sites in 1 country155 target enrollmentDecember 2002

ConditionsNon-Small Cell Lung Cancer

DrugsVELCADE™ (bortezomib) for Injection (formerly PS-341)

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Non-Small Cell Lung Cancer
Sponsor: Millennium Pharmaceuticals, Inc.
Enrollment: 155
Locations: 20
Status: Completed
Last Updated: 18 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate how tumors in patients with non-small cell lung cancer respond to treatment with VELCADE alone versus VELCADE given with docetaxel and also to see what effects (good and bad) it has on you and your cancer.

Detailed Description

In this study, patients with non-small cell lung cancer that is no longer responding to standard medical treatment with another anti-cancer drug will be randomly chosen to receive treatment with VELCADE alone or VELCADE in combination with docetaxel. Patients have almost equal chance of getting into either of the two treatment arms listed above.

Registry

clinicaltrials.gov

Start Date

December 2002

End Date

September 2004

Last Updated

18 years ago

Study Type

Interventional

Study Design

Parallel